What does this research mean for the field?

Dupilumab is a safe and effective treatment for drug-induced bullous pemphigoid, providing rapid relief of pruritus and serving as a viable alternative for patients who fail conventional therapies or need to continue the triggering medication. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the clinical efficacy and safety of dupilumab in patients with drug-induced bullous pemphigoid who failed or could not tolerate conventional therapies.

September 3, 2026Clinical Cosmetic and Investigational DermatologyOpen Access

Dupilumab for Drug-Induced Bullous Pemphigoid: A Case Series and Literature Review

View Full Paper

Ask AI

Bookmark

Authors

NSNawara Sakpuwadol SRSuthinee Rutnin WIWimolsiri Iamsumang

Discussion

Member takes

Overview

Case series and literature review reports rapid symptom resolution with dupilumab in drug-induced bullous pemphigoid, suggesting a safe steroid-sparing alternative for multimorbid patients.

Key Points

To evaluate the clinical efficacy and safety of dupilumab in patients with drug-induced bullous pemphigoid who failed or could not tolerate conventional therapies.
Assessed 4 patients with drug-induced bullous pemphigoid linked to dipeptidyl peptidase-4 inhibitors (n=3) or an immune checkpoint inhibitor (n=1).
Administered dupilumab following failure or intolerance of standard immunosuppressants and synthesized findings with existing literature.
All 4 patients achieved marked reduction in pruritus within 2 weeks of initiating dupilumab.
Complete clinical remission occurred in 3 patients within 1 to 5 months, and 1 patient achieved disease stabilization enabling resumption of pembrolizumab for cancer treatment.
No significant adverse events were documented across the treatment periods.

Cite This Study

Sakpuwadol et al. (2026) studied this question.

synapsesocial.com/papers/6a9934ea636c6408cfa7ca48 https://doi.org/10.2147/ccid.s619965

View Full Paper

Ask AI

Bookmark

September 3, 2026Clinical Cosmetic and Investigational DermatologyOpen Access

Dupilumab for Drug-Induced Bullous Pemphigoid: A Case Series and Literature Review

View Full Paper

Ask AI

Bookmark

Authors

NSNawara Sakpuwadol SRSuthinee Rutnin WIWimolsiri Iamsumang

Discussion

Member takes

Overview

Case series and literature review reports rapid symptom resolution with dupilumab in drug-induced bullous pemphigoid, suggesting a safe steroid-sparing alternative for multimorbid patients.

Key Points

To evaluate the clinical efficacy and safety of dupilumab in patients with drug-induced bullous pemphigoid who failed or could not tolerate conventional therapies.
Assessed 4 patients with drug-induced bullous pemphigoid linked to dipeptidyl peptidase-4 inhibitors (n=3) or an immune checkpoint inhibitor (n=1).
Administered dupilumab following failure or intolerance of standard immunosuppressants and synthesized findings with existing literature.
All 4 patients achieved marked reduction in pruritus within 2 weeks of initiating dupilumab.
Complete clinical remission occurred in 3 patients within 1 to 5 months, and 1 patient achieved disease stabilization enabling resumption of pembrolizumab for cancer treatment.
No significant adverse events were documented across the treatment periods.

Cite This Study

Sakpuwadol et al. (2026) studied this question.

synapsesocial.com/papers/6a9934ea636c6408cfa7ca48 https://doi.org/10.2147/ccid.s619965

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark